Navigation Links
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Date:10/26/2007

eeting pre-defined Responder criteria (p=0.009).

In the study, 229 patients with ADHD aged 18-65 years were randomized to receive CONCERTA(R) 36-108 mg/day or placebo, for seven weeks. The final analysis set contained data from 226 patients(a). Patients in the CONCERTA(R) group received a starting dose of 36 mg/day and the dose was increased in 18 mg increments every seven days (+/-2 days) for up to five weeks until response (AISRS scores decreased by 30% and CGI-I rating of 1 "very much" or 2 "much" improved) was achieved or titration to the maximum dose of 108 mg. The dose could be reduced one time during the study for tolerability reasons. The mean final dose was 67.7 mg/day.

Adverse events were reported by 93 (84.5%) of patients in the CONCERTA(R) group compared with 74 (63.8%) in the placebo group. The most commonly reported adverse events with CONCERTA(R) included decreased appetite (25.5%), headache (25.5%), dry mouth (20%), anxiety (16.4%), nausea (12.7%), increased blood pressure (10%), insomnia (9.1%), initial insomnia (7.3%), increased heart rate (7.3%), bruxism (6.4%), irritability (6.4%) and muscle tightness (6.4%). There were no serious treatment emergent adverse events reported and 16 (14.5%) and 6 (5.2%) subjects in the CONCERTA(R) and placebo groups, respectively, discontinued due to adverse events.

Today's data presentation included interim results from a long-term, open-label safety study. A similar dose titration protocol was used as in the double-blind study during the first weeks of the study after which the dose was flexible within the range of 36 to 108 mg. Interim results show that CONCERTA(R) was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months.

About ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is a common and treatable neuropsychiatric condition, which includes inattention, hyperactivity and impulsivity. According to the National Institut
'/>"/>

SOURCE McNeil Pediatrics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... database. Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... on Global and China Potassium Nitrate  Industry" is ... China and Global Potassium Nitrate ...
(Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... (NYSE-Amex: NBS ) today announced that it intends to ... an underwritten public offering. All of the shares and warrants in ... to market conditions, and there can be no assurance as to ... the actual size or terms of the offering. The shares will ...
... Ohio, July 18, 2011 BioTech Medical, Inc. announces the ... Dental Chair Pad and Head Cushion to its ... "There isn,t a day that goes by that our ... Tippey, Director of Medical Operations for BioTech Medical, Inc.  "We ...
Cached Medicine Technology:NeoStem Announces Proposed Public Offering of Common Stock 2NeoStem Announces Proposed Public Offering of Common Stock 3
(Date:8/1/2014)... Everett, WA (PRWEB) August 01, 2014 ... a problem throughout your entire home.“ In a newly ... Space or Attic Insulation Needs To Be Replaced ,” ... has deteriorated, become damp, or been infested by critters. ... space cleaning quote from Clean Crawls - http://www.cleancrawl.com/contact ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The Multiple System ... to serving patients, caregivers and families affected by the neurological ... Kramer Sutton of La Coste, TX to its Board of ... of 39 years, Eric Sutton. He was diagnosed officially with ... at home with his family. Like many others with this ...
(Date:8/1/2014)... 01, 2014 Narrow networks that ... and employers effective options to trim pharmacy costs ... that they can enhance formulary compliance and achieve ... report that nearly all PBMs now include a ... proposals. The Aug. 12 webinar from Atlantic ...
(Date:8/1/2014)... 01, 2014 Millions of women suffer ... legs and in some cases the arms, causing an ... about 17 million women in the U.S. alone are ... with the pain, embarrassment and discomfort caused by lipedema, ... physicians are unaware that this is a disease,” says Dr. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Get the ... partnership with PitchBook presents the 3Q 2014 Private Equity ... private equity investment, exits and fundraising activity in the ... to help plan for private equity endeavors for the ... form to download it now. , About Merrill DataSite ...
Breaking Medicine News(10 mins):Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2
... Nov. 21 Inverness Medical,Innovations, Inc. (Amex: IMA ... offering on Tuesday. The Company sold a total,of 13,634,302 ... of $61.49,per share. The total number of shares sold ... upon their exercise of their,over-allotment option in full. Certain ...
... The precise tailoring of tumor target treatment for patients ... to only administer treatments that have a high probability ... on imaging technologies, which are used to detect tumors ... guide therapy or surgery. , Vascular endothelial growth ...
... arterial vascular disease is widespread and often deadly among ... and treat it, according to a new report by ... Medical Center and Weill Cornell Medical College campuses of ... the fact that for years, cardiovascular research has focused ...
... Portable M5 Diagnostic Imaging Systems, SHENZHEN, China, ... MR ), a leading developer, manufacturer,and marketer ... growing,international presence, today announced that it will attend ... in Chicago,Illinois at the McCormick Place from November ...
... 21 Genomic Health,Inc. (Nasdaq: GHDX ) ... and Chief Executive Officer, will present at the ... on November 28, 2007 at 1:00,p.m. Eastern Time., ... webcast of the,presentation, visit the Investor Relations section ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... Merrill Lynch Health Services Investor Conference,taking place next ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will present ... a.m. Eastern time. Interested parties are invited to,listen ...
Cached Medicine News:Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:Mindray to Attend 2007 RSNA Conference in Chicago 2Health News:Mindray to Attend 2007 RSNA Conference in Chicago 3Health News:Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: